基因名 | 疾病 | 靶向药 | 化疗药 | 基因突变 | 临床解释 |
---|---|---|---|---|---|
IDH1 | 急性髓性白血病,间变性少突胶质瘤,星形细胞瘤,脑胶质瘤,神经节胶质瘤,多形胶质母细胞瘤,肝内胆管癌,恶性胶质瘤,骨髓增生异常综合征,胰腺导管腺癌。 | AG-120,AGI-5198,BAY 1436032,贝伐单抗,Bis-2-[5-(phenylacetamide)-1,帕纳替尼/普纳替尼/波纳替尼,4-thiadiazol-2-yl]ethyl Sulfide,Bis-2-(5-phenylacetamido-1,舒尼替尼,4-thiadiazol-2-yl)ethyl Sulfide,西妥昔单抗,达沙替尼,GSK321,Tibsovo,奥拉帕利,替莫唑胺, | 7 | 40 | |
IDH2 | 急性髓性白血病,星形细胞瘤,脑胶质瘤,多形性胶质母细胞瘤,骨髓增生异常综合征,外周T细胞淋巴瘤 | 恩西地平, | 4 | 18 | |
IKZF1 | 急性淋巴细胞白血病,小儿B细胞淋巴细胞白血病,前体B淋巴细胞淋巴瘤/白血病 | 2 | 6 | ||
IGF2 | 卵巢癌,胰腺腺癌,前列腺癌 | 卡巴他赛,Ganitumab,Linsitinib, | 多西他赛, | 1 | 4 |
IL7R | 小儿B淋巴细胞白血病,T细胞急性淋巴细胞白血病 | 3 | 3 | ||
IGF1R | 非小细胞肺癌 | 吉非替尼,IGF1R Monoclonal Antibody, | 2 | 2 | |
IL2RB | 小儿B细胞急性淋巴细胞白血病 | 1 | 1 | ||
IRS2 | 结直肠癌 | BMS-754807, | 1 | 1 | |
IGF2R | 0 | 0 | |||
INPP4B | 0 | 0 | |||
IKBKE | 0 | 0 | |||
INHBA | 0 | 0 | |||
IRF4 | 0 | 0 | |||
IRF2 | 0 | 0 | |||
ICOSLG | 0 | 0 | |||
ID3 | 0 | 0 | |||
IDO1 | 0 | 0 | |||
IDO2 | 0 | 0 | |||
IFNG | 0 | 0 | |||
IFNGR1 | 0 | 0 | |||
IGF1 | 0 | 0 | |||
IKBKB | 0 | 0 | |||
IL10 | 0 | 0 | |||
IL6 | 0 | 0 | |||
IL6R | 0 | 0 | |||
IL6ST | 0 | 0 | |||
INHA | 0 | 0 | |||
INPP4A | 0 | 0 | |||
INPPL1 | 0 | 0 | |||
INSR | 0 | 0 | |||
ITK | 0 | 0 | |||
ITPA | 0 | 0 | |||
Iars | 0 | 0 | |||
Ick | 0 | 0 | |||
ID2 | 0 | 0 | |||
IFITM1 | 0 | 0 | |||
IFITM3 | 0 | 0 | |||
IFNAR1 | 0 | 0 | |||
IFNAR2 | 0 | 0 | |||
IFNGR2 | 0 | 0 | |||
IFNL3 | 0 | 0 | |||
IGFL3 | 0 | 0 | |||
IGLL5 | 0 | 0 | |||
IGSF10 | 0 | 0 | |||
IKZF2 | 0 | 0 | |||
IKZF3 | 0 | 0 | |||
IL1RAPL1 | 0 | 0 | |||
IL21R | 0 | 0 | |||
IMPG1 | 0 | 0 | |||
ING1 | 0 | 0 | |||
INPP5D | 0 | 0 | |||
INSRR | 0 | 0 | |||
IP6K1 | 0 | 0 | |||
IPO7 | 0 | 0 | |||
IQCJ | 0 | 0 | |||
IRAK1 | 0 | 0 | |||
IRF1 | 0 | 0 | |||
IRF6 | 0 | 0 | |||
IRF8 | 0 | 0 | |||
IRS1 | 0 | 0 | |||
ITGAL | 0 | 0 | |||
ITGB2 | 0 | 0 | |||
ITGB3 | 0 | 0 | |||
ITPR2 | 0 | 0 | |||
ITSN1 | 0 | 0 |